NeuroSAFE-guided robot-assisted prostatectomy improves erectile function and continence in men

This is a systematic review and meta-analysis of studies comparing NeuroSAFE-guided robot-assisted radical prostatectomy (RARP) to standard RARP in men with prostate cancer. The analysis synthesized data from 22,183 patients across included studies. The intervention was NeuroSAFE-guided RARP, a technique aimed at enhancing nerve preservation during surgery, compared to standard RARP. The primary outcome was not reported in the source data. Key secondary outcomes included postoperative erectile function, urinary continence recovery, positive surgical margins, and biochemical recurrence.

For postoperative erectile function, the meta-analysis found a significant improvement with NeuroSAFE guidance. The effect size was an odds ratio (OR) of 2.00, with a 95% confidence interval (CI) of 1.46 to 2.74. For urinary continence recovery, results were also significantly improved, with an OR of 1.36 (95% CI 1.05 to 1.76). The rate of positive surgical margins was significantly reduced with NeuroSAFE, with an OR of 0.73 (95% CI 0.59 to 0.89). In contrast, no significant differences were observed for biochemical recurrence, with an OR of 0.81 (95% CI 0.43 to 1.56).

Safety and tolerability findings were limited. The source reports that adverse events, serious adverse events, and discontinuations were not reported. The overall tolerability was described as safe, but specific rates are unavailable. This lack of detailed safety data is a notable gap in the evidence.

These results can be compared to prior landmark studies in prostate cancer surgery, which have historically focused on oncologic outcomes like positive margins and recurrence. The current meta-analysis highlights functional outcomes, such as erectile function and continence, which are increasingly important to patients. The findings suggest NeuroSAFE may offer advantages in these domains, but direct comparison to prior trials is constrained by the different outcome emphases.

Key methodological limitations include substantial heterogeneity for some outcomes and a serious risk of bias in most nonrandomized studies included in the review. The authors note that these limitations limit causal inference. The nonrandomized nature of most evidence means observed associations cannot be interpreted as definitive proof of cause and effect.

Clinically, these results support integrating NeuroSAFE into surgical decision-making for patients undergoing RARP, particularly when nerve preservation can be achieved without compromising oncologic outcomes. However, clinicians should weigh the functional benefits against the limitations of the current evidence base.

Unanswered questions remain. The review does not report long-term follow-up data, specific patient subgroups that may benefit most, or detailed cost-effectiveness analyses. Future randomized trials are needed to confirm these findings and address the noted biases.